The association of GH treatment with improved arterial stiffness remained significant in models including CKD-MBD parameters and CV risk factors, BP and BMI, may suggest its independent beneficial effect on CV morbidity in CKD patients. The gene discussed is GH1; the disease is chronic kidney disease.